NOVO NORDISK
Wed, 03 Aug 2022 10:32:00 -0400
Wed, 03 Aug 2022 10:32:00 -0400
Financial report for the period 1 January 2022 to 30 June 2022
PROFIT AND LOSS |
H1 2022 | H1 2021 |
Growth as reported | Growth at CER* |
USD million |
|
|
|
|
Net sales | 12,238 | 10,837 | 25% | 16% |
Operating profit | 5,515 | 4,825 | 26% | 14% |
|
|
|
|
|
Net profit | 4,044 | 4,012 | 11% | N/A |
Diluted earnings per share (in USD) | 1.77 | 1.74 | 13% | N/A |
* CER: Constant exchange rates (average 2021).
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first half of 2022. The growth is driven by increasing demand for GLP-1 based diabetes treatments, especially Ozempic®. Our obesity treatments are also contributing to growth as more people living with obesity are being treated and the Obesity care market continues to expand. The performance in the first six months has enabled us to raise our outlook for the full year."
On 3 August 2022 at 19.30 CEST, corresponding to 1.30 pm EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.